Peptide library › Cancer & imaging
Motixafortide
Also known as Aphexda
Injection that releases stem cells from the bone marrow so they can be collected before a transplant for multiple myeloma.
What people use it for
- Stem cell mobilisation before autologous transplant in multiple myeloma
What Motixafortide does in the body
Blocks CXCR4, the receptor that anchors stem cells in the bone marrow, so they move into the blood where they can be collected. It's used with filgrastim.
Strength of evidence
Strong: the Phase 3 GENESIS trial collected enough stem cells in more patients with fewer collection sessions.
Look up the evidence
- Reviews on PubMed: Summaries of the published research
- Clinical trials on PubMed: Published studies in people
- ClinicalTrials.gov: Registered trials, past and ongoing
- Prescribing information (DailyMed, US): Official US label
- Patient leaflets (emc, UK): Official UK product information
Live searches of official databases. New to the terms? See the glossary.
Reported side effects & risks
- Injection-site reactions
- Itching and flushing
- Allergic reactions, so premedication is given
Who should avoid it or take extra care
- Known allergy to motixafortide
Not a complete list. Check with a doctor or pharmacist about your own health and medicines.
Regulatory status
FDA-approved in 2023. Given in specialist centres with premedication.
How it's taken
Route: Injection under the skin before stem cell collection
How long it lasts (half-life): About 2 hours
Storage
Stored and prepared by the pharmacy or clinic, following the product label.
Keep track of Motixafortide privately
Fiala is a free app for logging doses, tracking vials and setting reminders. No account, and everything you log stays on your phone.
Open Motixafortide in Fiala How to installMore in Cancer & imaging
- DegarelixMonthly hormone-blocking injection for advanced prostate cancer that lowers testosterone fast, without an initial flare.
- Lutetium Lu-177 dotatateTargeted radiation therapy that delivers radiation straight to neuroendocrine tumours.
- Lutetium Lu-177 vipivotide tetraxetanTargeted radiation therapy for advanced prostate cancer that carries the PSMA protein.
- Gallium Ga-68 dotatateRadioactive tracer used in PET scans to find neuroendocrine tumours.
- BalixafortideExperimental CXCR4 blocker studied with chemotherapy for advanced breast cancer; its Phase 3 trial failed.
- LTX-315Experimental cancer-killing peptide injected directly into tumours to trigger an immune response.